BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations

• Published in: Human pathology 2015-02, Vol.46 (2), p.239-245
• Main Authors: Piris, Adriano, MD, Mihm, Martin C., MD, Hoang, Mai P., MD
• Format: Article
• Language: English
• Subjects: BAP1; Biomarkers, Tumor - analysis; Biomarkers, Tumor - metabolism; BRAFV600E; Cell Proliferation - physiology; Humans; Immunohistochemistry; Immunohistochemistry - methods; Melanoma; Melanoma - genetics; Melanoma - metabolism; Melanoma - pathology; Metastasis; Morphology; Mutation; Mutation - genetics; Nevi; Nevus, Epithelioid and Spindle Cell - genetics; Nevus, Epithelioid and Spindle Cell - metabolism; Nevus, Epithelioid and Spindle Cell - pathology; Paraneoplastic Syndromes, Ocular; Pathology; Pregnancy; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins B-raf - metabolism; Skin cancer; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; Tumors; Ubiquitin Thiolesterase - genetics; Ubiquitin Thiolesterase - metabolism
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2014.10.015

Summary BAP1 (BRCA1-associated protein 1) is a tumor suppressor gene whose mutations have recently been reported to increase susceptibility for the development of uveal melanoma, cutaneous atypical and epithelioid melanocytic lesions, clear cell renal cell carcinoma, and other tumors. Screening for BAP1 mutation/loss/inactivation and BRAF V600E mutation can be done by immunohistochemistry. We investigated BAP1 and BRAFV600E expression in 193 sporadic melanocytic lesions (11 dermal nevi, 20 congenital nevi, 40 primary and nondesmoplastic melanomas, 40 desmoplastic melanomas, 23 metastatic melanomas, 17 Spitz nevi, 19 atypical Spitz nevi, 8 atypical Spitz tumors, 14 proliferative nodules arising in congenital nevi, 1 nevus during pregnancy) and 30 melanocytic lesions from 3 patients with family history of uveal melanoma and BAP1 germline mutation. Most sporadic melanocytic lesions exhibited positive BAP1 nuclear staining, except for 1 proliferative nodule arising in congenital nevus, 1 desmoplastic, 1 nevoid, and 2 metastatic melanomas. BRAFV600E positivity was demonstrated in 80% of dermal, 5% of congenital, 6% of Spitz, and 5.5% of atypical Spitz nevi; 29% of proliferative nodules arising in congenital nevi; and 24% of primary and nondesmoplastic and 35% of metastatic melanomas. Combined BAP1 loss and BRAFV600E staining was seen in 67% of BAP1 tumor syndrome–associated lesions and in none of the sporadic melanocytic proliferations including Spitz and atypical Spitz nevi and atypical Spitz tumors, with the exception of 1 primary melanoma. The combined BAP1-BRAFV600E+ immunoprofile appears to be a constant feature of BAP1 tumor syndrome–associated melanocytic lesions, and the designation of Spitz nevi or variants thereof appears to be inaccurate for this group of lesions.